|

News

BioTelemetry, Inc. Acquires Sweden-based ADEA Medical AB and Expands International Service Offering

MALVERN, Pa., July 24, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that it has acquired ADEA Medical AB, an early-stage Swedish medical technology company that delivers remote health services in the Nordics. The acquisition is aligned with BioTelemetry’s longer-term strategy to increase its international footprint and offer its products and services to physicians and patients in the Nordics and other parts of Europe. BioTelemetry advances health by providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects in a more efficient, accurate and cost-effective manner. Through its BioTel Heart division, BioTelemetry processes over

BioTelemetry, Inc. to Release Second Quarter 2019 Earnings Results on July 30, 2019

MALVERN, Pa., July 19, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2019 earnings on Tuesday, July 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, July 30, 2019.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on our website for two weeks. About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials and original

Geneva Health Solutions, a BioTelemetry company, Featured at Heart Rhythm Society Scientific Session

Managing vast data from implantable cardiac devices requires a transformative technology and service platform Geneva Health Solutions a leading solutions provider of technology-enabled services in the implantable cardiac device space, and a BioTelemetry, Inc. company (NASDAQ:BEAT), released its cardiac device data findings at the 40th Annual (2019) Heart Rhythm Society (HRS) conference. Geneva’s proprietary cloud-based platform aggregates data from leading cardiac device manufacturer systems and provides physicians and their staff a single workflow portal to manage patient device monitoring data, review and sign reports and integrate data with the electronic medical record. It is the only company that combines a proven enterprise platform and a quality service. The Geneva remote monitoring service helps cardiology providers manage the data deluge from these cardiac devices, including implantable

BioTelemetry President and CEO Joseph H. Capper Named Healthcare CEO of the Year at 26th Annual PACT Enterprise Awards

MALVERN, Pa., May 15, 2019 (GLOBE NEWSWIRE) — BioTelemetry (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that Joseph H. Capper, President and CEO, has been awarded the 2019 Healthcare CEO of the Year Award by the Philadelphia Alliance for Capital and Technologies, or PACT. The Healthcare CEO of the Year Award recognizes leaders for their management accomplishments and philosophy, including the communication of a vision and goals as achieved by the company. Leadership and impact in the industry and/or market, ability to attract and retain talented resources, financial accomplishments, strategy for continued success as well as community and industry involvement are also considered. Extra consideration is given

BioTelemetry, Inc. Reports First Quarter 2019 Financial Results

Achieves Record Quarterly Revenue Raises Full Year 2019 Guidance MALVERN, Pa., April 25, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the first quarter ended March 31, 2019. Quarter Highlights Recognized record quarterly revenue of $104.0 million Reached 10.0% year-over-year revenue growth Achieved 27th consecutive quarter of year-over-year revenue growth Reported GAAP net income of $11.7 million Realized quarterly adjusted EBITDA of $28.8 million, or 27.7% of revenue Completed the acquisition of Geneva Healthcare Raises full year 2019 revenue guidance to $446 to $450 million President and CEO Commentary Joseph H. Capper, President and Chief Executive Officer of BioTelemetry,

BioTelemetry, Inc. to Release First Quarter 2019 Earnings Results on April 25, 2019

MALVERN, Pa., April 18, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2019 earnings on Thursday, April 25 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Thursday, April 25, 2019.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on our website for two weeks. About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials and original

BioTelemetry, Inc. Completes Acquisition of Geneva Healthcare, Inc.

MALVERN, Pa., March 04, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that the Company has completed its acquisition of Geneva Healthcare, Inc., the leading provider of remote monitoring for implantable cardiac devices. Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “We are excited to welcome the Geneva team to BioTelemetry. This talented group of individuals has significantly transformed the way physician offices consolidate and manage data from implantable cardiac devices, giving precious time back to the staff to focus on patient care. Geneva’s market-leading platform and service, along with our scale and resources, make a formidable

BioTelemetry, Inc. Elects Laura Dietch and Tiffany Olson to its Board of Directors

MALVERN, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today the election of Laura Dietch and Tiffany Olson to BioTelemetry’s Board of Directors. Ms. Dietch has more than twenty-five years of experience in the medical device industry as a Chief Executive Officer, company co-founder, director, fundraiser, inventor, and mentor. She is currently the President and Chief Executive Officer of BioTrace Medical, Inc., a commercial stage cardiovascular medical device company, which she co-founded and has led from inception. Ms. Dietch has gained extensive executive and operating experience in both private and public companies, having been a member of the senior management

BioTelemetry, Inc. Reports Fourth Quarter 2018 Financial Results

Delivered Best Performance in Company’s History Exceeded Expectations  MALVERN, Pa., Feb. 21, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter ended December 31, 2018. Quarter Highlights Recognized quarterly revenue of $103.6 million Reached 12.9% year-over-year revenue growth Achieved 26th consecutive quarter of year-over-year revenue growth Reported GAAP net income of $10.4 million, or $0.29 per diluted share Realized record quarterly adjusted EBITDA of $30.5 million, or 29.4% of revenue President and CEO Commentary Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “I am pleased to report another outstanding growth quarter, with the highest revenue